List of Tables
    Table 1. Gene Modifying Immunotherapy for Blood Cancer Market Opportunities & Trends in Global Market
    Table 2. Gene Modifying Immunotherapy for Blood Cancer Market Drivers in Global Market
    Table 3. Gene Modifying Immunotherapy for Blood Cancer Market Restraints in Global Market
    Table 4. Key Players of Gene Modifying Immunotherapy for Blood Cancer in Global Market
    Table 5. Top Gene Modifying Immunotherapy for Blood Cancer Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Gene Modifying Immunotherapy for Blood Cancer Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Gene Modifying Immunotherapy for Blood Cancer Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Gene Modifying Immunotherapy for Blood Cancer Product Type
    Table 9. List of Global Tier 1 Gene Modifying Immunotherapy for Blood Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Gene Modifying Immunotherapy for Blood Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Gene Modifying Immunotherapy for Blood Cancer Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2023-2028
    Table 30. Novartis Corporate Summary
    Table 31. Novartis Gene Modifying Immunotherapy for Blood Cancer Product Offerings
    Table 32. Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
    Table 33. Kite Pharma Corporate Summary
    Table 34. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Product Offerings
    Table 35. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
    Table 36. Juno Therapeutics Corporate Summary
    Table 37. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Product Offerings
    Table 38. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
    Table 39. Cellectis Corporate Summary
    Table 40. Cellectis Gene Modifying Immunotherapy for Blood Cancer Product Offerings
    Table 41. Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
    Table 42. Ziopharm Oncology Corporate Summary
    Table 43. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Product Offerings
    Table 44. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
    Table 45. Celyad Corporate Summary
    Table 46. Celyad Gene Modifying Immunotherapy for Blood Cancer Product Offerings
    Table 47. Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
    Table 48. Bluebird Bio Corporate Summary
    Table 49. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Product Offerings
    Table 50. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
    Table 51. Bellicum Pharmaceuticals Corporate Summary
    Table 52. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Product Offerings
    Table 53. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
    Table 54. Mustang Bio Corporate Summary
    Table 55. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Product Offerings
    Table 56. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Gene Modifying Immunotherapy for Blood Cancer Segment by Type in 2021
    Figure 2. Gene Modifying Immunotherapy for Blood Cancer Segment by Application in 2021
    Figure 3. Global Gene Modifying Immunotherapy for Blood Cancer Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Gene Modifying Immunotherapy for Blood Cancer Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Gene Modifying Immunotherapy for Blood Cancer Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Gene Modifying Immunotherapy for Blood Cancer Revenue in 2021
    Figure 8. By Type - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
    Figure 12. US Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
    Figure 16. Germany Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 17. France Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
    Figure 24. China Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 28. India Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
    Figure 30. Brazil Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Revenue Market Share, 2017-2028
    Figure 33. Turkey Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Gene Modifying Immunotherapy for Blood Cancer Revenue, (US$, Mn), 2017-2028
    Figure 37. Novartis Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Kite Pharma Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Juno Therapeutics Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Cellectis Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Ziopharm Oncology Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Celyad Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Bluebird Bio Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Bellicum Pharmaceuticals Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. Mustang Bio Gene Modifying Immunotherapy for Blood Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)